Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5705094 | Ophthalmology | 2017 | 8 Pages |
Abstract
Intravitreous melphalan is an effective treatment for vitreous seeding in retinoblastoma, resulting in high rates of ocular survival and disease-free survival. However, in this study, each injection of melphalan was associated, on average, with a decrement in ERG response. The findings suggest increased toxicity (1) when OAC is given within 1 week of the intravitreous injection and (2) in more deeply pigmented eyes.
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
Jasmine H. MD, FACS, Scott E. MD, PhD, Brian MD, Emily C. MS, Ijah MD, David H. MD, FACS,